Partsch G
Ludwig Boltzmann Institute of Rheumatology, Vienna-Oberlaa, Austria.
Arzneimittelforschung. 1992 Nov;42(11):1336-8.
Two pyrazolon derivatives--mofebutazone (CAS 2210-63-1) and phenylbutazone (CAS 50-33-9)--were compared as to their effects on the adenosine triphosphate (ATP) level of polymorphonuclear cells (PMNs) and their response to the migration of these cells. In the range of 10(-8) to 10(-3) mol/l neither mofebutazone nor phenylbutazone significantly changed the ATP level of PMNs. Compared to the untreated PMNs only phenylbutazone reduced the migration of PMNs significantly (chemotactic index (CI) 0.46) at a concentration of 10(-3) mol/l. On the other hand with mofebutazone no statistically significant abnormality on PMN migration was found. Direct statistical comparisons of the migration between specific concentrations of the two pharmaceuticals did not indicate a different migration behavior even at 10(-3) mol/l. These results show that in contrast to the chemical and pharmacological differences of mofebutazone and phenylbutazone their effect on the ATP level and the migration of PMNs is comparable.